Bionutrics, Inc. Launches a New Cardiovascular Product.

Business Editors

PHOENIX--(BUSINESS WIRE)--February 14, 2001

Bionutrics, Inc., (Nasdaq: BNRX) announced today that it is launching a new cardiovascular product under the brand name, "CARDIO-CIN(TM) -- For Heart and Health".

This new product, based on Bioneutric's patented niacin and soluble fiber composition, is targeted to the cholesterol dietary supplement market. The global market for products addressing cholesterol reduction exceeds $8 billion annually. Sales of niacin-based and fiber-formulated foods and dietary supplements are nearly $2 billion annually. Both markets have been, and are growing rapidly.

A double blind clinical trial at the University of Miami employing Bionutrics' proprietary technology, has demonstrated average reductions of 22% for LDL-cholesterol and 10% for triglycerides, In addition the trial results indicated an increase of 8% in HDL-cholesterol, the good cholesterol 

Bionutrics Health Products' Vice President of Sales and Marketing, Richard Mott, commented "We have great expectations for CARDIO-CIN(TM). The medical and consumer communities have long appreciated the advantages of both fiber and niacin for cholesterol management. Our new product and it's trial results echo similar findings reported on November 13, 2000, by Merck & Co which demonstrated that patients who took niacin plus the statin drug, simvastatin (Zocor(R), which is designed to lower cholesterol and the risk of heart disease), experienced plunging cholesterol levels. Bionutrics patented release modification technology has been clinically proven to provide niacin in the easily tolerated doses required for healthy cholesterol results and the addition of the fiber component of the product further contributes to its beneficial cardiovascular effects. We believe the market for this type of product is quite sizable and that there are multiple channels for potential distribution. Bionutrics will initially target CARDIO-CIN(TM) for market introduction through Direct-Sales companies. Direct-Sales companies have a large share of the dietary supplement market and represent an excellent opportunity for the Company to achieve early consumer acceptance and success."

Ronald H. Lane, Ph.D., Bionutrics Chairman and CEO remarked: "The launch of CARDIO-CIN(TM) is a very important event for our Company. For the past two years we have been structuring Bionutrics as a product development company. During this period we have been conducting research and developing new product candidates. The launch of CARDIO- CIN(TM) is an important step in that undertaking. We expect further announcements about new products and new technologies in the near future as we continue to move forward with this product development strategy."

Bionutrics is a biopharmaceutical company founded to discover and develop novel biologically active compounds derived from natural sources. Natural, biologically active compounds have potential applications as functional nutrition ingredients as well as ethical drugs. Bionutrics is presently developing proprietary functional nutrition ingredients and pharmaceutical products and intends to market these products through strategic alliances.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This release contains forward looking statements that are subject to the risks and uncertainties, including, but not limited to, the impact of competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw materials, the regulatory environment and governmental approval processes, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.